Boston Scientific (BSX) Cash from Financing Activities (2009 - 2026)

Boston Scientific has reported Cash from Financing Activities for 18 years, with the latest figure at -$410.0 million in Q2 2026.

• Cash from Financing Activities for Q2 2026 came in at -$410.0 million, down 20.59% year-over-year; the trailing twelve-month figure through Jun 2026 was -$958.0 million (down 940.35% YoY), and the FY2025 annual result was -$395.0 million, down 121.78% from the prior year.
• Cash from Financing Activities declined to -$410.0 million in Q2 2026, from -$260.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $1.6 billion in Q1 2024 and troughed at -$410.0 million in Q2 2026.
• A 5-year average of $11.4 million and a median of -$2.5 million in 2022 frame the typical range for Cash from Financing Activities.
• The widest annual swing landed in 2022, when Cash from Financing Activities slumped 17300.0%; it then soared 2373.91% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $1.0 million in 2022, then surged by 1400.0% to $15.0 million in 2023, then jumped by 1326.67% to $214.0 million in 2024, then slumped by 185.98% to -$184.0 million in 2025, then plunged by 122.83% to -$410.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$410.0 million in Q2 2026, -$260.0 million in Q1 2026, and -$184.0 million in Q4 2025.